Victoria Johnson

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

The rheumatology month in review emphasizes new approvals and the latest comparative research.

Risankizumab shows significant and lasting improvements in psoriatic arthritis symptoms, addressing multiple disease domains and enhancing patient quality of life.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Study data favored the placebo group, although differences were not clinically meaningful.

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

The rheumatology month in review emphasizes new approvals and best-in-class efficacy data.

The FDA has approved the therapy, marketed as Wayrilz, a new treatment for chronic immune thrombocytopenia.

Regeneron is planning a BLA submission for the first quarter of 2026.

This FDA News Month in Review provides a round-up of regulatory decisions from August 2025.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

Despite high cardiovascular risk with the 2 comorbidities, no beneficial effect was seen with colchicine.

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

A recent study reveals gout patients face higher chronic opioid prescription rates.

Rosnilimab shows promising long-term efficacy in treating moderate-to-severe rheumatoid arthritis.

The therapy, marketed as Tonmya, is a sublingual formulation of cyclobenzaprine HCl.

SetPoint Medical's FDA-approved device offers a new neuroimmune therapy for rheumatoid arthritis, enhancing treatment options without immune risks.

Novartis is planning regulatory submissions for the therapy, which could become the first to meaningfully modify disease activity.

New research reveals challenges in maintaining urate-lowering therapy for gout, highlighting disparities in adherence among diverse patient populations.

New findings reveal CFT outperformed usual care to significantly reduce chronic low back pain and activity limitations.

The rheumatology month in review emphasizes new research in psoriatic arthritis treatments and data from EULAR 2025.

Guselkumab shows promise as the first IL-23 inhibitor to significantly reduce joint damage in active psoriatic arthritis.

Reformer Pilates significantly reduces pain and enhances mental and physical health in women with chronic musculoskeletal pain, promoting active living and coping strategies.